

*the*  **DBL** *report*

**UPDATE**

**Update, December 2001**

*An Official Accompaniment to  
the Alberta Health Drug Benefit List (AHDBL)*

*The Expert Committee on Drug Evaluation and  
Therapeutics (ECDET)*

*produced by Alberta Blue Cross*

---

**EXPERT COMMITTEE MEMBERS:**

D. Neil Graham, M.D., FRCP (C), FACP (Chair)  
Judith M. Baker, BSc (Pharm), MSc., PhD  
Norman Campbell, BMed Sc, M.D., FRCP (C)  
William F. Dryden, BSc (Pharm), PhD ARCST  
Erwin G. Friesen, BSc (Pharm), Pharm. D., FCSHP  
Fakhreddin Jamali, Pharm. D., PhD  
Stephen C. Newman, MSc., M.D., CCFP  
James Silvius, BA, M.D., FRCP (C)

**ALBERTA HEALTH AND WELLNESS**

**LIAISON:**

David Bougher, BSP, MHSA

**ADMINISTRATIVE AND**

**SCIENTIFIC SUPPORT:**

Larry Shipka, BSc (Pharm)  
Eugenia Palylyk-Colwell, BSc (Pharm), PhD  
Carlyn Volume, BSc (Pharm), MSc

---

## ***Interchangeability of Warfarin Sodium Preparations***

On December 01, 2001, the warfarin sodium preparation, **APO-WARFARIN**, will be designated as an interchangeable drug product with **Coumadin** and **Taro-Warfarin** on the Alberta Health and Wellness Drug Benefit List (AHWDBL).

In conducting its review of Apo-Warfarin, the Expert Committee followed up on its commitment to ensure that additional generic warfarin products would be reviewed as stringently as the first generic entrant, Taro-Warfarin. Due to concerns over generic to generic substitution, the Expert Committee and Alberta Health and Wellness sought assurance that Apo-Warfarin sold in Alberta would be manufactured to the same stringent manufacturing specifications (that exceed USP requirements) as Coumadin and Taro-Warfarin. Apotex Inc. has provided that assurance and consequently, Apo-Warfarin will be designated as interchangeable effective December 01, 2001.